ESC Congress 2025: Vutrisiran Demonstrates Sustained Cardiovascular Benefits in Landmark HELIOS-B Study for ATTR-CM Patients
Madrid, Spain – New analyses from the pivotal HELIOS-B Phase 3 study of vutrisiran (AMVUTTRA®) have revealed compelling long-term cardiovascular benefits for patients suffering from transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Presented at the highly popular European Society of Cardiology (ESC) Congress 2025, these findings underscore vutrisiran’s potential to significantly alter the course of this progressive…
